maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri
Company profile
Ticker
MRVI
Exchange
Website
CEO
Carl W. Hull
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Maravai Topco Holdings, LLC • Maravai Intermediate Holdings, LLC • Alphazyme, LLC • Cygnus Technologies, LLC • Maravai LifeSciences International Holdings, Inc. • MLSA Holdings, LLC • MockV Solutions, LLC • TriLink Biotechnologies, LLC • Glen Research, LLC • MyChem, LLC ...
MRVI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Feb 24
8-K
Maravai Lifesciences Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Maravai Lifesciences Reports Third Quarter 2023 Financial Results
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Maravai Lifesciences Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition
27 Jul 23
8-K
Maravai LifeSciences Announces Appointment of New Director to the Board
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
22 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
Transcripts
MRVI
Earnings call transcript
2023 Q4
22 Feb 24
MRVI
Earnings call transcript
2023 Q3
7 Nov 23
MRVI
Earnings call transcript
2023 Q2
7 Aug 23
MRVI
Earnings call transcript
2023 Q1
8 May 23
MRVI
Earnings call transcript
2022 Q4
22 Feb 23
MRVI
Earnings call transcript
2022 Q3
3 Nov 22
MRVI
Earnings call transcript
2022 Q2
7 Aug 22
MRVI
Earnings call transcript
2022 Q1
9 May 22
MRVI
Earnings call transcript
2021 Q4
24 Feb 22
MRVI
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 579.61 mm | 579.61 mm | 579.61 mm | 579.61 mm | 579.61 mm | 579.61 mm |
Cash burn (monthly) | 190.33 k | 3.15 mm | 6.85 mm | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 1.30 mm | 21.57 mm | 46.88 mm | n/a | n/a | n/a |
Cash remaining | 578.30 mm | 558.04 mm | 532.72 mm | n/a | n/a | n/a |
Runway (months of cash) | 3038.4 | 177.0 | 77.7 | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 199 |
Opened positions | 28 |
Closed positions | 46 |
Increased positions | 94 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 1.31 tn |
Total shares | 279.57 mm |
Total puts | 158.10 k |
Total calls | 288.80 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Maravai Life Sciences Holdings 2 | 145.35 mm | $6.09 bn |
GTCR | 21.68 mm | $216.81 bn |
Thrivent Financial For Lutherans | 11.84 mm | $118.02 bn |
Vanguard | 10.22 mm | $102.17 bn |
Massachusetts Financial Services | 8.15 mm | $81.53 bn |
12 West Capital Management | 6.46 mm | $64.63 bn |
BLK Blackrock | 5.93 mm | $59.27 bn |
MKFCF Mackenzie Financial | 4.93 mm | $48.67 bn |
Millennium Management | 4.26 mm | $42.62 bn |
Braidwell | 3.97 mm | $39.75 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Andrew Burch | Class A Common Stock | Payment of exercise | Dispose F | No | No | 8.11 | 16,758 | 135.91 k | 420,035 |
15 Mar 24 | Christine Dolan | Class A Common Stock | Payment of exercise | Dispose F | No | No | 7.7 | 5,383 | 41.45 k | 258,007 |
15 Mar 24 | Kurt Oreshack | Class A Common Stock | Payment of exercise | Dispose F | No | No | 7.7 | 4,551 | 35.04 k | 223,349 |
15 Mar 24 | Peter Michael Leddy | Class A Common Stock | Payment of exercise | Dispose F | No | No | 7.7 | 6,714 | 51.70 k | 376,359 |
15 Mar 24 | Kevin Herde | Class A Common Stock | Payment of exercise | Dispose F | No | No | 7.7 | 8,624 | 66.40 k | 332,914 |
News
Craig-Hallum Initiates Coverage On Maravai LifeSciences with Buy Rating, Announces Price Target of $15
10 Apr 24
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
9 Apr 24
Nasdaq Edges Lower; AXT Shares Surge After Q4 Results
23 Feb 24
Small-Cap Maravai LifeSciences' Q4 Outperforms Expectations, Analyst shows Optimism Around 2024 Guidance
23 Feb 24
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
23 Feb 24
Press releases
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
18 Apr 24
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
10 Apr 24
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
8 Mar 24
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
28 Feb 24
Thinking about buying stock in Maravai Lifesciences, Abercrombie & Fitch, elf Beauty, IONQ, or Vanda Pharmaceuticals?
23 Feb 24